This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sarepta May Have Found Treatment Breakthrough for Muscular Dystrophy

The significant, relative improvement in walking ability was sustained when Sarepta analyzed six patients, including two patients treated with a lower, 30 mg dose of eteplirsen. Another two patients treated at the lower dose were excluded because they experienced a sudden and rapid decline in function soon after the study started.

There was no difference in walking ability between patients treated exclusively with the lower eteplirsen dose compared to the control arm, Sarepta said.

Sarepta continues to follow the patients in the study and will have updated results after 48 weeks of treatment ready for presentation at a medical conference in October. On a conference call Tuesday, Sarepta said if the benefit observed in the 36-week data are confirmed at 48 weeks, the company will meet with FDA to discuss regulatory options.

One of those options could be an accelerated approval filing under new FDA regulations designed to speed the development of drugs for rare diseases. Sarepta would still have to conduct a larger clinical trial to confirm eteplirsen's benefit, but the trial could be done post approval.

Last April, Sarepta presented data showing eteplirsen treatment for six months resulted in a statistically significant increase in the production of dystrophin compared to placebo.

Dystrophin is a protein that plays key role in muscle function and repair. The genetic inability to make dystrophin is what causes muscular dystrophy. Eteplirsen is designed to "skip over" the section of damaged gene in DMD patients and therefore restore the gene's ability to produce partially functioning dystrophin.

In many ways, the science Sarepta is using to find an effective treatment for DMD is similar to the work done successfully by Vertex Pharmaceuticals (VRTX - Get Report) to find new treatments for the underlying cause of cystic fibrosis, another rare, genetic disease.

What was missing from the April eteplirsen data -- until Tuesday -- was evidence linking increased production of dystrophin to an improved ability to walk. The new data suggests that longer treatment is required before meaningful levels of dystrophin are produced such that it significantly delays progression of DMD and improves walking function, Sarepta said.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
SRPT $26.13 7.70%
VRTX $125.12 0.06%
AAPL $132.54 0.88%
FB $80.58 0.12%
GOOG $540.32 -0.40%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs